Addressing unmet needs in rare diseases and systemic complement mediated disorders

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenience

Superior Outcomes

A leader in the field of engineered protease biopharmaceuticals

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenience

Superior Outcomes

Protease engineering platform – hemophilia assets in development and a SQ systemic complement research program

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenience

Superior Outcomes

Next Generation Hemostasis Programs

Learn more about our Pipeline

FVIIa: marzeptacog alfa (activated)
Hemophilia A or B with Inhibitors
Phase 2
FIX: dalcinonacog alfa
Hemophilia B
Phase 2
SQ Systemic complement inhibitors
 
Research

Learn more about our Factor VIIa marzeptacog alfa (activated) trial

The Catalyst Advantage

Drug candidates for severe medical conditions

Learn more about the medicines we are developing

See our Pipeline

Addressing diseases with unmet medical needs

Share our passion about treating disease

Learn more about Hemophilia

We have an experienced and passionate team

Learn more about the Catalyst team and mission/culture

Meet the team